IDSA Revises CCP Recommendation for Some Ambulatory Patients

February 16, 2022

The Infectious Diseases Society of America (IDSA) recently issued a revised recommendation for the use of COVID-19 convalescent plasma (CCP) in ambulatory patients at high risk for progression to severe disease who have no other effective treatment options. Based on new on newly available literature and approvals, the IDSA guideline panel now suggests the use of FDA-qualified high-titer CCP within 8 days of symptom onset rather than no high-titer CCP. The complete IDSA Guideline on the Treatment and Management of COVID-19 is available online.